儿童与青少年非转移性横纹肌肉瘤:欧洲儿童软组织肉瘤研究组RMS2005研究总体结果
RMS2005研究包含高危组的两项III期随机试验及低危、标准危、极高危组的观察性试验,本次报告完整非转移性队列结果。中位随访73.1个月,1733例患者5年无事件生存(EFS)为70.7%(95%CI 68.5~72.8),总生存(OS)为80.4%(95%CI 78.4~82.3)。研究显示约80%局限期横纹肌肉瘤患儿可长期生存,并确立了欧洲儿童软组织肉瘤研究组各国的标准治疗。
要点
- 1733例非转移性横纹肌肉瘤患者5年EFS为70.7%、OS为80.4%。
- 低危组80例5年EFS 93.7%、OS 96.7%,极高危组150例EFS 48.8%、OS 49.7%。
- 研究确认低危22周长春新碱/放线菌素D方案,高危省略多柔比星并加维持化疗。
核心结论
- RMS2005研究显示约80%的局限期横纹肌肉瘤患儿可成为长期生存者。
- 该研究确立了欧洲儿童软组织肉瘤研究组各国的标准治疗,包括低危22周长春新碱/放线菌素D方案、标准危组降低异环磷酰胺累积剂量、高危组省略多柔比星并加用维持化疗。
研究设计与样本
- RMS2005研究包含高危组的两项III期随机试验,以及低危、标准危和极高危组的观察性试验,上述试验此前已部分报告。
- 本文对完整、未选择的非转移性队列进行综合报告,并与既往欧洲方案比较治疗演变。
- 共纳入1733例患者,中位随访73.1个月。
主要发现
- 全部1733例患者5年无事件生存(EFS)为70.7%(95%CI 68.5~72.8),5年总生存(OS)为80.4%(95%CI 78.4~82.3)。
- 低危组(80例)5年EFS 93.7%(95%CI 85.5~97.3),OS 96.7%(95%CI 87.2~99.2)。
- 标准危组(652例)5年EFS 77.4%(95%CI 73.9~80.5),OS 90.6%(95%CI 87.9~92.7)。
- 高危组(851例)5年EFS 67.3%(95%CI 64.0~70.4),OS 76.7%(95%CI 73.6~79.4)。
- 极高危组(150例)5年EFS 48.8%(95%CI 40.4~56.7),OS 49.7%(95%CI 40.8~57.9)。
关键数值与推荐
- 低危组采用22周长春新碱/放线菌素D方案。
- 标准危组降低异环磷酰胺累积剂量。
- 高危组省略多柔比星并加用维持化疗。
临床怎么用
- RMS2005研究确立的方案已成为欧洲儿童软组织肉瘤研究组各国的标准治疗。
- 低危患者采用22周长春新碱/放线菌素D方案。
- 标准危患者降低异环磷酰胺累积剂量。
- 高危患者省略多柔比星并加用维持化疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.The RMS2005 study included two phase III randomized trials for high-risk (HR) and observational trials for low (LR), standard (SR), and very high-risk (VHR) patients who have been partially reported. Herein, we present a comprehensive report of results achieved for the complete unselected nonmetastatic cohort and analyze the evolution of treatment in comparison with previous European protocols. After a median follow-up of 73.1 months, the 5-year event-free survival (EFS) and overall survival (OS) of the 1,733 patients enrolled were 70.7% (95% CI, 68.5 to 72.8) and 80.4% (95% CI, 78.4 to 82.3), respectively. The results by subgroup: LR (80 patients) EFS 93.7% (95% CI, 85.5 to 97.3), OS 96.7% (95% CI, 87.2 to 99.2); SR (652 patients) EFS 77.4% (95% CI, 73.9 to 80.5), OS 90.6% (95% CI, 87.9 to 92.7); HR (851 patients) EFS 67.3% (95% CI, 64.0 to 70.4), OS 76.7% (95% CI, 73.6 to 79.4); and VHR (150 patients) EFS 48.8% (95% CI, 40.4 to 56.7), OS 49.7% (95% CI, 40.8 to 57.9). The RMS2005 study demonstrated that 80% of children with localized rhabdomyosarcoma could be long-term survivors. The study has established the standard of care across the European pediatric Soft tissue sarcoma Study Group countries with the confirmation of a 22-week vincristine/actinomycin D regimen for LR patients, the reduction of the cumulative ifosfamide dose in the SR group, and for HR disease, the omission of doxorubicin and the addition of maintenance chemotherapy.
引用
- Bisogno G, Minard-Colin V, Zanetti I, et al. Nonmetastatic Rhabdomyosarcoma in Children and Adolescents: Overall Results of the European Pediatric Soft Tissue Sarcoma Study Group RMS2005 Study. J Clin Oncol. 2023. PMID: 36848614. doi:10.1200/JCO.22.02093
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。